Applied DNA Sciences (NASDAQ:APDN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a report released on Saturday morning. The firm issued a sell rating on the technology company’s stock.

Separately, HC Wainwright cut their price objective on Applied DNA Sciences from $7.00 to $1.50 and set a buy rating on the stock in a research note on Monday, June 10th.

Applied DNA Sciences Trading Up 33.4 %

Shares of NASDAQ APDN opened at $0.55 on Friday. Applied DNA Sciences has a one year low of $0.37 and a one year high of $37.20. The business has a 50-day moving average price of $1.94 and a two-hundred day moving average price of $7.72. The firm has a market capitalization of $534,100.00, a PE ratio of -0.03 and a beta of 0.09.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings results on Friday, May 10th. The technology company reported ($5.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.60) by ($0.71). Applied DNA Sciences had a negative return on equity of 306.32% and a negative net margin of 222.33%. The firm had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.90 million. Research analysts anticipate that Applied DNA Sciences will post -2.95 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC bought a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned about 0.72% of Applied DNA Sciences as of its most recent SEC filing. 22.22% of the stock is currently owned by institutional investors.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.